OKYO Pharma (NASDAQ:OKYO) stock jumped 14% Wednesday after announcing encouraging Phase 2 clinical trial results for urcosimod, their investigational drug aimed at neuropathic corneal pain (NCP). The ...

The mission is quiet, but not still. Here's what the ship’s activity tells us about Phase 2 of the search. Gavin Newsom's warning to Donald Trump over plan for Texas Republicans ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

It’ll be the 5th and 6th ones they’ve built so far. This partnership has been in the making since 2022, and Bright Community Trust broke ground on their first houses here in Gainesville in 2024. The ...

New Phase II data presented at ENDO 2025 highlight avexitide’s potential to significantly reduce severe hypoglycemic events ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

After the Grenfell fire there are many lessons to be learned. Architects and manufacturers should be able to demonstrate they ...

The Waukee City Council could consider taking action at its July 21 meeting that would allow work to begin on the second phase of the Waukee Towne Center project, a project the developer says is ...

Amirco Properties, a real estate company, is expected to break ground on the 4-acre, multi-building development—dubbed ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

Thunderbolts* introduced one of the MCU's most powerful heroes, but a new theory suggests his abilities are connected to an age-old villain.

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...